First Page | Document Content | |
---|---|---|
Date: 2016-07-11 21:31:12Clinical medicine Breakthrough therapy Medicine Antineoplastic drugs Pharmacology Monoclonal antibodies Bristol-Myers Squibb Nivolumab Melanoma Programmed cell death protein 1 Pembrolizumab Raltegravir | 12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO BoxAdd to Reading ListSource URL: www.nzma.org.nzDownload Document from Source WebsiteFile Size: 204,40 KBShare Document on Facebook |
Breakthrough Cancer Therapy DTCDocID: 1sYyU - View Document | |
Microsoft Word - GILEAD BRIEFINGDocID: 1r2Vm - View Document | |
Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatioDocID: 1qWZQ - View Document | |
24 MayDanae Staples-Moon Therapeutic Group Manager PHARMAC PO BoxDocID: 1qVSm - View Document | |
12-AUG:10 CANCER CONTROL ACCRUAL REPORT STUDY ODocID: 1qRuM - View Document |